Related Products of 1346697-39-9, With the rapid development and complex challenges of chemical substances, the synthesis of new drugs is usually one of the most effective ways to increase yield.1346697-39-9, name is 5-Bromo-4-cyclopropylpyrimidine, molecular formula is C7H7BrN2, molecular weight is 199.05, as common compound, the synthetic route is as follows.
Example 397- 4-Cyclopropylpyrimidin-5 -yl)-3 -(5 -fluoro-2-methoxyphenyl)benzo [d] isoxazole[00211] A reaction vial was charged with tetrakis(triphenylphosphine)palladium(0) (5.78 mg, 5.00 ?????), Preparation 36A (0.037 g, 0.100 mmol), sodium carbonate (42.4 mg, 0.400 mmol), and Preparation 1 1A (29.9 mg, 0.150 mmol). The mixture was stirred at room temperature for 10 min under N2, then DME (Ratio: 2.0, Volume: 373 ??), EtOH (Ratio: 1.0, Volume: 187 ??), and water (Ratio: 1.000, Volume: 187 ??) were added sequentially. The resultant mixture was heated at 90 C overnight. After 14 hr, the reaction mixture was allowed to cool to room temperature. The reaction was quenched with water. The reaction mixture was diluted with EtOAc. The layers were separated and the aqueous phase was extracted with EtOAc (3X). The organic phases were combined, dried over Na2S04, filtered, and concentrated to afford a brown residue. The crude material was purified via preparative LC/MS with the following conditions:Column: Waters XBridge CI 8, 19 x 250 mm, 5-??? particles; Guard Column: Waters XBridge C18, 19 x 10 mm, 5-??? particles; Mobile Phase A: 5:95 acetonitrile:water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile:water with 10-mM ammonium acetate; Gradient: 15-100% B over 25 minutes, then a 5-minute hold at 100% B; Flow: 20 mL/min. Fractions containing the desired product were combined and dried via centrifugal evaporation. The material was further purified via preparative LC/MS with the following conditions: Column: Waters XBridge CI 8, 19 x 250 mm, 5-??? particles; Guard Column: Waters XBridge CI 8, 19 x 10 mm, 5-??? particles; Mobile Phase A: 5:95 acetonitrile:water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile:water with 10-mM ammonium acetate; Gradient: 35-70% B over 25 minutes, then a 5-minute hold at 100% B; Flow: 20 mL/min. Fractions containing the desired product were combined and dried via centrifugal evaporation to afford the title compound (9.4 mg, 26%). ESI MS (M+H)+ = 362.2. HPLC Peak tr = 2.81 minutes. Purity >99%. HPLC Conditions: B.
Statistics shows that 1346697-39-9 is playing an increasingly important role. we look forward to future research findings about 5-Bromo-4-cyclopropylpyrimidine.
Reference:
Patent; BRISTOL-MYERS SQUIBB COMPANY; BALOG, James Aaron; HUANG, Audris; VELAPARTHI, Upender; LIU, Peiying; WO2013/49263; (2013); A1;,
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia